Cardiol Therapeutics Inc. Class A Company Profile
NASDAQ: CRDLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Cardiol Therapeutics at a glance
Cardiol Therapeutics Inc. Class A (NASDAQ: CRDL) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Oakville, ON, Canada. Cardiol Therapeutics is led by Mr. David G. Elsley MBA and employs about 18 people. At a market capitalization of $159.3 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001702123, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Cardiol Therapeutics do?
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Business description based on the company's public filings.
Company information
- Legal name
- Cardiol Therapeutics Inc. Class A
- Ticker
- NASDAQ: CRDL
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. David G. Elsley MBA
- Employees
- 18
- Headquarters
- 2265 Upper Middle Road East, Oakville, ON, Canada
- Phone
- 289 910 0850
- Website
- cardiolrx.com
- Market cap
- $159.27M
- SEC CIK
- 0001702123
Companies similar to Cardiol Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TARAProtara Therapeutics Inc. | 2.65 | +2.32% | $156.60M | vs CRDL |
| CHRSCoherus Oncology Inc. | 1.07 | +5.94% | $165.32M | vs CRDL |
| ABOSAcumen Pharmaceuticals Inc. | 2.10 | 0.00% | $151.87M | vs CRDL |
| VYGRVoyager Therapeutics Inc. | 2.37 | -4.05% | $146.03M | vs CRDL |
| MOLNMolecular Partners AG ADR | 3.81 | 0.00% | $145.94M | vs CRDL |
| ARMPArmata Pharmaceuticals Inc. | 3.86 | +1.31% | $143.52M | vs CRDL |
| AVXLAnavex Life Sciences Corp. | 1.54 | +0.65% | $142.75M | vs CRDL |
| CMPXCompass Therapeutics Inc. | 0.9834 | -3.59% | $177.10M | vs CRDL |